This commentary discusses the role of IL-17 in the depression associated with chronic immune-mediated diseases. It uses as a model disease that of psoriatic disease, because there is a consensus regarding the pivotal role of IL-17 mediated immunity in the induction of psoriasis and psoriatic arthritis in a considerable proportion of the affected patients. We argue that if IL-17 plays a role in the induction of depression and/or its progression overtime, patients treated with blockers of IL-17 must show a significant improvement, and that their improvement must be analogous to- or closely related to- the extent of IL-17 inhibition. Though we understand that such a scenario is very simplistic, taking into account the complex interaction between the brain and the affected tissues, we postulate that it can be still possible to dissect the underlying pathophysiological mechanisms, if the focus of the translational research is to be directed towards assessing the IL-17 axis and its relation to brain development and depressive disorders.
Close
Τα cookies είναι σημαντικά για την εύρυθμη λειτουργία του ιστοτόπου και την βελτίωση της online εμπειρίας σας. Πατήστε "Αποδοχή" για να συνεχίσετε!ΑποδοχήΠερισσότερες πληροφορίες